BioArctic AB Class B (DE:B9A)
FRANKFURT:B9A
Holding DE:B9A?
Track your performance easily

BioArctic AB Class B (B9A) Stock Price & Analysis

11 Followers

B9A Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%1.67%1.66%96.67%
0.00%
Insiders
1.66% Other Institutional Investors
96.67% Public Companies and
Individual Investors

B9A FAQ

What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was €12.80 and its highest was €25.62 in the past 12 months.
    What is BioArctic AB Class B’s market cap?
    Currently, no data Available
    When is BioArctic AB Class B’s upcoming earnings report date?
    BioArctic AB Class B’s upcoming earnings report date is Nov 14, 2024 which is in 55 days.
      How were BioArctic AB Class B’s earnings last quarter?
      BioArctic AB Class B released its earnings results on Aug 29, 2024. The company reported -€0.068 earnings per share for the quarter, missing the consensus estimate of -€0.067 by >-€0.001.
        Is BioArctic AB Class B overvalued?
        According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does BioArctic AB Class B pay dividends?
          BioArctic AB Class B pays a Notavailable dividend of €0.13 which represents an annual dividend yield of N/A. See more information on BioArctic AB Class B dividends here
            What is BioArctic AB Class B’s EPS estimate?
            BioArctic AB Class B’s EPS estimate is -€0.06.
              How many shares outstanding does BioArctic AB Class B have?
              BioArctic AB Class B has 73,659,990 shares outstanding.
                What happened to BioArctic AB Class B’s price movement after its last earnings report?
                BioArctic AB Class B reported an EPS of -€0.068 in its last earnings report, missing expectations of -€0.067. Following the earnings report the stock price went up 2.028%.
                  Which hedge fund is a major shareholder of BioArctic AB Class B?
                  Currently, no hedge funds are holding shares in DE:B9A
                  ---

                  BioArctic AB Class B Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -41.64%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -9.66%
                  Trailing 12-Months
                  Asset Growth
                  8.16%
                  Trailing 12-Months

                  Company Description

                  BioArctic AB Class B

                  BioArctic AB is a research-based biopharmaceutical company. It is primarily focused on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of revenue from Asia.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Bank of Tianjin Co., Ltd. Class H
                  Raubex Group Limited
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis